In this video, James Ferrara MD, DSc, and Mariano Prado-Acosta, PhD, Icahn School of Medicine at Mount Sinai, New York City, NY, outline the rationale for targeting receptor interactive protein kinase 1 (RIP1) in patients with acute graft-versus-host disease (GvHD) and discuss the results of a pre-clinical study evaluating the potential of genetic and pharmacological RIP1 inhibition in in vitro intestinal organoids and in vivo mouse models. Prof. Ferrara and Dr Prado-Acosta explain that RIP1 inhibition rescued organoids from apoptosis, and in mouse GvHD models, RIP1 inhibition was able to prevent mortality, reverse GvHD damage, and improve survival, whilst preserving the graft-versus-leukemia (GvL) effect. This method represents a promising alternative to immunosuppressive drugs that expose patients to infections after transplant. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть